Study on the predictive value of pretreatment peripheral blood inflammatory markers regarding immunotherapy in patients with inoperable advanced or locally advanced oesophageal squamous cell carcinoma

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi: 10.3322/caac.21660.
   PubMed Web of Science ®Google Scholar
• Arnold M, Soerjomataram I, Ferlay J, et al. Global incidence of oesophageal cancer by histological subtype in 2012. Gut. 2015;64(3):381–387. doi: 10.1136/gutjnl-2014-308124.
   PubMed Web of Science ®Google Scholar
• Sheikh M, Poustchi H, Pourshams A, et al. Individual and combined effects of environmental risk factors for esophageal cancer based on results from the golestan cohort study. Gastroenterology. 2019;156(5):1416–1427. doi: 10.1053/j.gastro.2018.12.024.
   PubMed Web of Science ®Google Scholar
• Allemani C, Matsuda T, Di Carlo V, et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018;391(10125):1023–1075. doi: 10.1016/S0140-6736(17)33326-3.
   PubMed Web of Science ®Google Scholar
• Huang FL, Yu SJ. Esophageal cancer: risk factors, genetic association, and treatment. Asian J Surg. 2018;41(3):210–215. doi: 10.1016/j.asjsur.2016.10.005.
   PubMed Web of Science ®Google Scholar
• Wang Z, Hu M, Hu Y, et al. Paclitaxel plus cisplatin and 5-fluorouracil induction chemotherapy for locally advanced borderline-resectable esophageal squamous cell carcinoma: a phase II clinical trial. Esophagus. 2022;19(1):120–128. doi: 10.1007/s10388-021-00864-8.
   PubMed Web of Science ®Google Scholar
• Sun JM, Shen L, Shah MA, et al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. Lancet. 2021;398(10302):759–771. doi: 10.1016/S0140-6736(21)01234-4.
   PubMed Web of Science ®Google Scholar
• Luo H, Lu J, Bai Y, et al. Effect of camrelizumab vs placebo added to chemotherapy on survival and progression-Free survival in patients with advanced or metastatic esophageal squamous cell carcinoma: the ESCORT-1st randomized clinical trial. JAMA. 2021;326(10):916–925. doi: 10.1001/jama.2021.12836.
   PubMed Web of Science ®Google Scholar
• Doki Y, Ajani JA, Kato K, et al. Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma. N Engl J Med. 2022;386(5):449–462. doi: 10.1056/NEJMoa2111380.
   PubMed Web of Science ®Google Scholar
• Obermannová R, Alsina M, Cervantes A, et al. Oesophageal cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(10):992–1004. doi: 10.1016/j.annonc.2022.07.003.
   PubMed Web of Science ®Google Scholar
• Ajani JA, D’Amico TA, Bentrem DJ, et al. Esophageal and esophagogastric junction cancers, version 2.2023, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2023;21(4):393–422. doi: 10.6004/jnccn.2023.0019.
   PubMedGoogle Scholar
• Zhang RX, Kang XZ, Zheng QF[, et al. Advances of immunotherapy-related biomarker in esophageal carcinoma]. Zhonghua Wei Chang Wai Ke Za Zhi. 2023;26:396–400.
   PubMedGoogle Scholar
• Salem ME, Puccini A, Xiu J, et al. Comparative molecular analyses of esophageal squamous cell carcinoma, esophageal adenocarcinoma, and gastric adenocarcinoma. Oncologist. 2018;23(11):1319–1327. doi: 10.1634/theoncologist.2018-0143.
   PubMed Web of Science ®Google Scholar
• Tsao MS, Kerr KM, Kockx M, et al. PD-L1 immunohistochemistry comparability study in Real-Life clinical samples: results of blueprint phase 2 project. J Thorac Oncol. 2018;13(9):1302–1311. doi: 10.1016/j.jtho.2018.05.013.
   PubMed Web of Science ®Google Scholar
• Xu J, Li Y, Fan Q, et al. Clinical and biomarker analyses of sintilimab versus chemotherapy as second-line therapy for advanced or metastatic esophageal squamous cell carcinoma: a randomized, open-label phase 2 study (ORIENT-2). Nat Commun. 2022;13(1):857. doi: 10.1038/s41467-022-28408-3.
   PubMed Web of Science ®Google Scholar
• Sun D, Liu J, Zhang L. Establishment of tumor immune microenvironment classification model to select patients sensitive to immunotherapy. J Thorac Oncol. 2023;18(10):e111–111e112. doi: 10.1016/j.jtho.2023.07.003.
   PubMed Web of Science ®Google Scholar
• Marazziti D, Torrigiani S, Carbone MG, et al. Neutrophil/lymphocyte, platelet/lymphocyte, and monocyte/lymphocyte ratios in mood disorders. Curr Med Chem. 2022;29(36):5758–5781. doi: 10.2174/0929867328666210922160116.
   PubMed Web of Science ®Google Scholar
• Feng J, Wang L, Yang X, et al. Pretreatment Pan-Immune-inflammation value (PIV) in predicting therapeutic response and clinical outcomes of neoadjuvant immunochemotherapy for esophageal squamous cell carcinoma. Ann Surg Oncol. 2023;31(1):272–283. doi: 10.1245/s10434-023-14430-2.
   PubMed Web of Science ®Google Scholar
• Kam AE, Masood A. The prognostic role of the neutrophil to lymphocyte ratio at recurrence in esophageal squamous cell carcinoma: challenges and future directions. Ann Surg Oncol. 2021;28(6):2939–2940. doi: 10.1245/s10434-021-09640-5.
   PubMed Web of Science ®Google Scholar
• Sasahara M, Kanda M, Shimizu D, et al. High preoperative platelet to lymphocyte ratio is associated with a greater risk of postoperative complications and hematogenous recurrences in esophageal squamous cell carcinoma patients receiving neoadjuvant treatment. Dig Surg. 2023;40(1-2):48–57. doi: 10.1159/000530018.
   PubMed Web of Science ®Google Scholar
• Guo W, Cai S, Zhang F, et al. Systemic immune-inflammation index (SII) is useful to predict survival outcomes in patients with surgically resected non-small cell lung cancer. Thorac Cancer. 2019;10(4):761–768. doi: 10.1111/1759-7714.12995.
   PubMed Web of Science ®Google Scholar
• Wang Y, Lyu J, Jia H, et al. Clinical utility of the systemic immune-inflammation index for predicting survival in esophageal squamous cell carcinoma after radical radiotherapy. Future Oncol. 2021;17(20):2647–2657. doi: 10.2217/fon-2021-0304.
   PubMed Web of Science ®Google Scholar
• Adegoke NA, Gide TN, Mao Y, et al. Classification of the tumor immune microenvironment and associations with outcomes in patients with metastatic melanoma treated with immunotherapies. J Immunother Cancer. 2023;11(10):e007144. doi: 10.1136/jitc-2023-007144.
   PubMed Web of Science ®Google Scholar
• Hirahara N, Matsubara T, Fujii Y, et al. Comparison of the prognostic value of immunoinflammation-based biomarkers in patients with gastric cancer. Oncotarget. 2020;11(27):2625–2635. doi: 10.18632/oncotarget.27653.
   PubMedGoogle Scholar
• Hara K, Aoyama T, Yamada T, et al. The prognostic value of the perioperative systemic inflammation score for patients with advanced gastric cancer. Anticancer Res. 2020;40(3):1503–1512. doi: 10.21873/anticanres.14095.
   PubMed Web of Science ®Google Scholar
• Huang H, Liu Q, Zhu L, et al. Prognostic value of preoperative systemic immune-inflammation index in patients with cervical cancer. Sci Rep. 2019;9(1):3284. doi: 10.1038/s41598-019-39150-0.
   PubMed Web of Science ®Google Scholar
• Binnewies M, Roberts EW, Kersten K, et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med. 2018;24(5):541–550. doi: 10.1038/s41591-018-0014-x.
   PubMed Web of Science ®Google Scholar
• Faria A, Andrade SS, Peppelenbosch MP, et al. Platelets in aging and cancer-"double-edged sword. Cancer Metastasis Rev. 2020;39(4):1205–1221. doi: 10.1007/s10555-020-09926-2.
   PubMed Web of Science ®Google Scholar
• Yang Y, Xu H, Zhou L, et al. Platelet to lymphocyte ratio is a predictive marker of prognosis and therapeutic effect of postoperative chemotherapy in non-metastatic esophageal squamous cell carcinoma. Clin Chim Acta. 2018;479:160–165. doi: 10.1016/j.cca.2018.01.013.
   PubMed Web of Science ®Google Scholar
• Gao Y, Guo W, Cai S, et al. Systemic immune-inflammation index (SII) is useful to predict survival outcomes in patients with surgically resected esophageal squamous cell carcinoma. J Cancer. 2019;10(14):3188–3196. doi: 10.7150/jca.30281.
   PubMed Web of Science ®Google Scholar
• Fucà G, Guarini V, Antoniotti C, et al. The Pan-Immune-inflammation value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the valentino and TRIBE first-line trials. Br J Cancer. 2020;123(3):403–409. doi: 10.1038/s41416-020-0894-7.
   PubMed Web of Science ®Google Scholar
• Feng J, Wang L, Yang X, et al. Clinical utility of preoperative pan-immune-inflammation value (PIV) for prognostication in patients with esophageal squamous cell carcinoma. Int Immunopharmacol. 2023;123:110805. doi: 10.1016/j.intimp.2023.110805.
   PubMed Web of Science ®Google Scholar
• Zhang H, Shang X, Ren P, et al. The predictive value of a preoperative systemic immune-inflammation index and prognostic nutritional index in patients with esophageal squamous cell carcinoma. J Cell Physiol. 2019;234(2):1794–1802. doi: 10.1002/jcp.27052.
   PubMed Web of Science ®Google Scholar